Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Indocyanine Green (IC-Green)
Indocyanine Green · 1 trial · 1 indication
• The distance (cm) that lymph travels from injection sites
• Number of lymph propulsion events per minute
| Arm | Type | Description |
|---|---|---|
| Treatment group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Advanced pneumatic compression device (APCD) | DEVICE | Single APCD treatment session at visit 1 |
| Advanced pneumatic compression device (APCD) with revised compression programming | DEVICE | APCD with revised compression programming will be single treatment session at visit 2 |
| Indocyanine Green (IC-Green) | DRUG | Indocyanine Green dye will be used to assess primary endpoint |
Inclusion Criteria: 1. 18 years of age or older 2. A diagnosis of active lower extremity lymphedema, as assessed by medical history 3. Participant is a candidate for APCD treatment per the Flexitouch Plus indications for use 4. Must be able to provide informed consent prior to study participation 5...
Indocyanine Green is being studied for use in lower extremity lymphedema. It is an investigational small molecule being developed by Tactile Systems Technology, Inc. The drug is currently in early Phase 1 clinical development for this condition.
Indocyanine Green is a small molecule being evaluated for lower extremity lymphedema. Its specific molecular target has not been disclosed in available clinical trial information. The drug is in early Phase 1 development.
Indocyanine Green is being developed by Tactile Systems Technology, Inc., a company traded on the NASDAQ under the ticker TCMD. The drug is currently in early Phase 1 clinical trials for lower extremity lymphedema.
Indocyanine Green is in early Phase 1 clinical development. It is an investigational drug being studied for lower extremity lymphedema, and it is not yet approved for any use. The ongoing trial is recruiting participants in the United States.
Indocyanine Green is being studied in one active clinical trial, NCT07613931, titled "Evaluate Advanced Pneumatic Compression Device With Revised Compression Programming for Lymphedema Treatment." This early Phase 1 trial is recruiting 5 participants with lower extremity lymphedema in the United States.
Yes, Indocyanine Green is also known as IC-Green. The drug is being developed by Tactile Systems Technology, Inc. for lower extremity lymphedema and is currently in early Phase 1 clinical trials.